{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:32:04Z","timestamp":1760189524941},"reference-count":25,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[1995,9,1]],"date-time":"1995-09-01T00:00:00Z","timestamp":809913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T00:00:00Z","timestamp":1577404800000},"content-version":"vor","delay-in-days":8883,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1995,9]]},"DOI":"10.1093\/oxfordjournals.annonc.a059282","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T13:54:55Z","timestamp":1486130095000},"page":"665-671","source":"Crossref","is-referenced-by-count":22,"title":["Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer"],"prefix":"10.1016","volume":"6","author":[{"given":"A.F.","family":"Scinto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ferraresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Campioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Tonachella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Piarulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cognetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0005","first-page":"6523","article-title":"Curative cancer chemotherapy","volume":"45","author":"Frei","year":"1985","journal-title":"Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/bjc.1987.226","article-title":"A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma","volume":"56","author":"Carmo-Pereira","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1200\/JCO.1988.6.9.1377","article-title":"Randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer","volume":"6","author":"Tannock","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.1992.10.1.102","article-title":"A phase II study of high-dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy","volume":"10","author":"Antman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0025","first-page":"321","article-title":"Schedule-dependent interaction of cytarabine plus doxorubicin or cytarabine plus mitoxantrone in acute myelogenic leukemia cells in culture","volume":"4","author":"Fountzilas","year":"1990","journal-title":"Leukemia"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0030","first-page":"1063","article-title":"Effect of 4\u2019-doxorubicin analogs on heterotransplantation of human tumors in congenitally athymic mice","volume":"65","author":"Giuliani","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0035","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1002\/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0","article-title":"Dose response evaluation of adriamycin in human neoplasia","volume":"39","author":"O\u2019Bryan","year":"1977","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.1987.5.3.354","article-title":"Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study","volume":"5","author":"Hortobagy","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0045","first-page":"79","article-title":"A randomized trial of high-dose 5-fluorouracil (F), doxorubicin (A) and cyclophosphamide (C) vs conventional FAC regimen in metastatic breast cancer","volume":"1","author":"Malik","year":"1982","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0050","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1200\/JCO.1991.9.12.2148","article-title":"A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer","volume":"9","author":"Perez","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0055","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.1991.9.2.295","article-title":"Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer The results of a randomized trial","volume":"9","author":"Habenshow","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0060","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF00688864","article-title":"High-dose epirubicin as primary chemotherapy in advanced breast carcinoma; a phase II study","volume":"27","author":"Carmo-Pereira","year":"1991","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0065","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/030089169107700309","article-title":"High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer","volume":"77","author":"Fountzilas","year":"1991","journal-title":"Tumori"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0070","first-page":"10","article-title":"Evaluation of the importance and relevance of dose intensity using Epirubicin and Cyclophosphamide in metastatic breast cancer Interim analysis of a prospective randomized trial","volume":"21","author":"Marschner","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0075","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/0959-8049(94)90174-0","article-title":"Phase II trial of high-dose epirubicin and cyclophosphamide in advanced breast cancer","volume":"30A","author":"Scinto","year":"1994","journal-title":"Eur J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(88)91475-4","article-title":"Effect of granulocyte colony-stimulating factor on neutropenia induced by cytotoxic chemotherapy","volume":"1","author":"Morstyn","year":"1988","journal-title":"Lancet"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0085","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/bjc.1987.295","article-title":"Phase I\/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small-cell lung cancer","volume":"56","author":"Bronchud","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0090","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","article-title":"Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium","volume":"318","author":"Gabrilove","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0095","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0100","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0105","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1002\/1097-0142(197703)39:3<1289::AID-CNCR2820390340>3.0.CO;2-F","article-title":"Assessment of response to therapy in advanced breast cancer. A project of the Programme on Clinical Oncology of International Union Against Cancer, Geneva, Switzerland","volume":"39","author":"Hayward","year":"1977","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0110","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/83.21.1546","article-title":"Effects of recombinant human granulocyte macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose-chemotherapy in patients with advanced breast cancer","volume":"83","author":"Hoeckman","year":"1991","journal-title":"J Nad Cancer Inst"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/bjc.1994.71","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose-intensity increase of CEF chemotherapy: A randomized study in patients with advanced breast cancer","volume":"69","author":"Ardizzoni","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/oxfordjournals.annonc.a058689","article-title":"Failure of GM-CSF to permit dose escalation in an every-other-week dose-intensive regimen for advanced breast cancer","volume":"5","author":"Osborne","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a059282_bb0125","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood.V80.6.1430.1430","article-title":"Granulocyte colonystimulating factor to prevent dose-limiting neutropenia in non-Hodgkin\u2019s lymphoma: A randomized controlled trial","volume":"80","author":"Pettengell","year":"1992","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419613050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419613050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/6\/7\/665\/373626\/6-7-665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T20:17:38Z","timestamp":1582229858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419613050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,9]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1995,9]]}},"alternative-id":["S0923753419613050"],"URL":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a059282","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1995,9]]}}}